On August 9, 2012, the company signed an ACTL technology research cooperation agreement with Nanfang Hospital in the No. 1 conference room. This also shows that the company has formally formed a strategic partnership with Nanfang Hospital.

         In a warm and friendly atmosphere, the two parties talked freely about the future cooperation development route, conducted in-depth discussions on the in-depth scientific research, clinical trial research, and clinical application of ACTL technology, and reached consensus.

         The company relies on its own patented technology ACTL-the world's leading targeted anti-tumor cell immune technology, and has a strong alliance with Nanfang Hospital, which has strong medical and scientific research capabilities. At the same time, they complement each other. Both parties firmly believe in targeted anti-tumor cell therapy. In the field, relying on their respective advantages, they will be able to achieve world-renowned results.